SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-009814
Filing Date
2020-08-07
Accepted
2020-08-07 07:31:50
Documents
80
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20200630x10q.htm   iXBRL 10-Q 2076385
2 EX-10.2 acrs-20200630xex10d2.htm EX-10.2 16818
3 EX-31.1 acrs-20200630xex31d1.htm EX-31.1 15710
4 EX-31.2 acrs-20200630xex31d2.htm EX-31.2 15716
5 EX-32.1 acrs-20200630xex32d1.htm EX-32.1 9492
  Complete submission text file 0001558370-20-009814.txt   8875905

Data Files

Seq Description Document Type Size
6 EX-101.SCH acrs-20200630.xsd EX-101.SCH 50885
7 EX-101.CAL acrs-20200630_cal.xml EX-101.CAL 59548
8 EX-101.DEF acrs-20200630_def.xml EX-101.DEF 173056
9 EX-101.LAB acrs-20200630_lab.xml EX-101.LAB 524591
10 EX-101.PRE acrs-20200630_pre.xml EX-101.PRE 358477
11 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20200630x10q_htm.xml XML 1966486
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 201083735
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences